▲9June 4-5   CBI Biomedical Innovation Expo Scan the QR code to register

Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information.This article is intended solely for the introduction of medications related to medical and health care; it does not constitute a recommendation for treatment plans (if any), nor does it represent the platform's position.Authorization is required for any article reposting.

PharmCube DataMonitoring shows: Recently, the newly established Bionyra Pharma in Paris, France, completed a funding round led by Jeito Capital, with participation from Sofinnova Partners (the earliest incubating institution) and direct investment from Sanofi.Sanofi Ventures a $165 million Series A financing round, oversubscribed and participated in by multiple global life sciences investment institutions.

Introduced multiple candidate new drug molecules from China. Among themMonoclonal antibody BYN‑001,FromCSPC's New StoneNovaRock Biotherapeutics BD in-licensing, this product is aIL-25 Monoclonal Antibody(Original Code: NBL-023)。

(Emerging from the Shadows, Antibody Rising Star Fanli: Secures Major BD Deal)

https://www.novarockbio.com/home/pipeline/

NovaRock Biotherapeutics' Rich Product Portfolio.Partners also includeAlso including LIGACHEM (formerly LEGOCHEM) under Orion, Kanion Pharmaceutical, and others.

Related Reading:

On January 15, 2024, South Korea's Orion Group announced the acquisition of LegoChem Biosciences (LCB).25.7%shares, investing approximately USD 418 million (equivalent to RMB 3 billion), thereby becoming theJiakesidaof listed companiesLargest Shareholder。

Follow the "YaoRongQuan" WeChat Official Account

References:

PharmCube Data;

FDA/EMA；

NMPA；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/n

ews-release；

https://www.businesswire.com/news/home；

Wait.